The Astounding Account of the IL-17 and Spondylarthritis

In this episode, we focus on the history of researchers discovering the clinical applicability of the IL 23/17 axis, with a particular emphasis on psoriasis, psoriatic arthritis and axial SpA Intro 0:15 In this episode 0:27 Leonard Calabrese, DO, is listening! 1:07 Recap of last episode 3:23 Putting the pieces together 5:32 Quick overview of this science heavy episode 6:27 What is psoriasis? 7:42 Immunosuppressants for psoriasis/ Throwing meds at people and seeing what happens 10:20 In the modern world of 1986 – olive oil placebo trial 11:45 A quick aside into fungi 12:44 What kind of T-cells are involved here? 16:50 The TH-1 hypothesis 18:31 IL-23 and IL-17 are doing something 19:38 Going back to the drawing board in 2004 20:12 p40 + p19 = IL-23 21:08 IL-23 via minicircle DNA in mice 23:09 Brand new and shiny TH-17 25:30 The family of IL-17 26:40 What do we know about IL-17 and psoriasis? 27:17 IL-17A vs IL-17F in mouse studies 27:42 Finding the difference between IL-17A and IL-17F in humans 28:30 What exactly is IL-17 doing? 29:51 The articular manifestations of psoriatic arthritis 31:13 Spondylarthritis and the IL 23/17 axis 34:10 T-cells we haven't talked about 35:49 Summary of this episode 39:17 Thanks for listening 41:38 We'd love to hear from you! Send your comments/questions to Dr. Brown at [email protected]. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bashyam H. J Exp Med. 2007;doi:10.1084/jem.2042fta Bjerke R J. Acta Derm Venereol. 1982;PMID:6179355 Cargill M, et al. Am J Hum Genet. 2007;doi:10.1086/511051 Chan J R, et al. J Exp Med. 2006;doi:10.1084/jem.20060244 Cuthbert R J, et al. Ann Rheum Dis. 2019;doi:10.1136/annrheumdis-2019-215210 Ellis C N, et al. JAMA. 1986;doi:10.1001/jama.1986​ Ettehadi P, et al. Clin Exp Immunol. 1994;doi:10.1111/j.1365-2249.1994.tb06244.x Furue M, et al. Int J Mol Sci. 2020;doi:10.3390/ijms21041275 Gooderham M J, et al. J Eur Acad Dermatol Venereol. 2018;doi:10.1111/jdv.14868 Lee E, et al. J Exp Med. 2004;doi:10.1084/jem.20030451 Leonardi C L, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60725-4 Mease P J, et al. Lancet. 2000;doi:10.1016/S0140-6736(00)02530-7 Menon B, et al. Arthritis Rheumatol. 2014;doi:10.1002/art.38376 Moos S, et al. J Invest Dermatol. 2019;doi:10.1016/j.jid.2019.01.006 Muelle W, et al. N Engl J Med. 1979;doi:10.1056/NEJM197909063011016 Papp K A, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60726-6 Reinhardt A, et al. Arthritis Rheumatol. 2016;doi:10.1002/art.39732 Sherlock J P, et al. Nat Med. 2012;doi:10.1038/nm.2817 Tribe H T. Mycologist. 1998;doi:10.1016/S0269-915X(98)80100-6 Yawalkar N, et al. J Invest Dermatol. 1998;doi:10.1046/j.1523-1747.1998.00446.x Zaba L C, et al. J Allergy Clin Immunol. 2009;doi:10.1016/j.jaci.2009.08.046   Disclosures: Brown reports no relevant financial disclosures.